ES2106728T3 - Dihidroespirorenona como agente antiandrogeno. - Google Patents

Dihidroespirorenona como agente antiandrogeno.

Info

Publication number
ES2106728T3
ES2106728T3 ES90250127T ES90250127T ES2106728T3 ES 2106728 T3 ES2106728 T3 ES 2106728T3 ES 90250127 T ES90250127 T ES 90250127T ES 90250127 T ES90250127 T ES 90250127T ES 2106728 T3 ES2106728 T3 ES 2106728T3
Authority
ES
Spain
Prior art keywords
dihydrespirorenone
androgen agent
treatment
androgen
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90250127T
Other languages
English (en)
Spanish (es)
Inventor
Sybille Dr Beier
Walter Dr Elger
Yukishige Dr Nishino
Rudolf Prof-Dr Wiechert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6380839&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2106728(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering AG filed Critical Schering AG
Application granted granted Critical
Publication of ES2106728T3 publication Critical patent/ES2106728T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Dental Preparations (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
ES90250127T 1989-05-16 1990-05-16 Dihidroespirorenona como agente antiandrogeno. Expired - Lifetime ES2106728T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3916112A DE3916112A1 (de) 1989-05-16 1989-05-16 Dihydrospirorenon als antiandrogen

Publications (1)

Publication Number Publication Date
ES2106728T3 true ES2106728T3 (es) 1997-11-16

Family

ID=6380839

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90250127T Expired - Lifetime ES2106728T3 (es) 1989-05-16 1990-05-16 Dihidroespirorenona como agente antiandrogeno.

Country Status (20)

Country Link
US (1) US5569652A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0398460B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2848919B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1033948C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE154881T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU642876B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR1101055A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2016780C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD (1) DD294417A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (3) DE3916112A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0398460T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2106728T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3024861T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU213408B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE81143B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL94416A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU91065I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300221I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT94038B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA903754B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4321957C2 (de) * 1993-07-01 1995-09-28 Marika Dr Med Ehrlich Verwendung eines hormonalen Mittels zur Therapie der Akne
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
EP2305267A3 (en) 1999-08-31 2011-08-17 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
NZ517845A (en) 1999-08-31 2004-12-24 Schering Ag Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
JP5350572B2 (ja) * 2000-12-20 2013-11-27 バイエル ファーマ アクチエンゲゼルシャフト シクロデキストリン−ドロスピレノン封入複合体
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
EP1216712A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes
JP2005522466A (ja) * 2002-03-18 2005-07-28 ファルマシア・コーポレーション アルドステロン受容体アンタゴニスト、およびニコチン酸またはニコチン酸誘導体の組合わせ
BR0308517A (pt) * 2002-03-18 2005-02-01 Pharmacia Corp Combinação de um antagonista do receptor de aldosterona e de um agente sequestrante de ácido biliar
WO2004070048A1 (en) * 2003-02-07 2004-08-19 Pharmacia & Upjohn Company Llc A microbial process to prepare 5-androsten-3beta, 7alpha, 15alpha-triol-17-one and related analogues
ATE429900T1 (de) * 2004-03-10 2009-05-15 Bayer Schering Pharma Ag Zusammensetzungen aus drospirenon in molekularer dispersion
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
US20050220825A1 (en) * 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone
DE102004026679A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026669A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
DE102004026670A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
ITMI20042338A1 (it) * 2004-12-06 2005-03-06 Ind Chimica Srl Processo per la preparazione di drospirenone
US8475838B2 (en) * 2005-06-03 2013-07-02 Sandoz Ag Rapidly-dissolving pharmaceutical composition for inhibiting ovulation
ES2311927T5 (es) * 2005-07-21 2014-09-08 Bayer Pharma Aktiengesellschaft Proceso para la producción de 3-oxo-pregn-4-en-21,17-carbolactonas por la oxidación sin metales de 17-(3-hidroxipropil)-3,17-dihidroxiandrostanos
US7319154B2 (en) 2005-07-21 2008-01-15 Bayer Schering Pharma Ag Process for the production of 3-oxo-pregn-4-ene-21, 17-carbolactones by the metal free oxidation of 17-(3-hydroxypropyl)-3, 17-dihydroxyandrostanes
US20070275941A1 (en) * 2006-05-17 2007-11-29 Vladimir Hanes Salt sensitivity and prevention of hypertension with drospirenone
CN102083418A (zh) * 2008-04-24 2011-06-01 伊万斯彻有限公司 口服避孕药剂及其制备方法
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3022337A1 (de) * 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
US4347245A (en) * 1981-05-26 1982-08-31 German Shapiro Spironolactone-containing composition and use thereof
JPS59139400A (ja) * 1983-01-31 1984-08-10 Shionogi & Co Ltd 抗アルドステロン活性ステロイド誘導体
DE3402329A1 (de) * 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US4855289A (en) * 1984-06-04 1989-08-08 Wester Per O Combination of two active substances
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
DE3615376A1 (de) * 1986-05-07 1987-11-12 Schering Ag 2,2;6,6-diethylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DK174724B1 (da) * 1986-07-15 2003-10-06 Wyeth Corp Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet

Also Published As

Publication number Publication date
JPH0395121A (ja) 1991-04-19
NL300221I1 (nl) 2006-04-03
DE59010730D1 (de) 1997-08-07
IL94416A (en) 1997-07-13
EP0398460A3 (de) 1991-09-25
DE122004000006I1 (de) 2006-06-08
PT94038B (pt) 1997-06-30
NL300221I2 (nl) 2006-11-01
ATE154881T1 (de) 1997-07-15
CA2016780C (en) 2000-07-11
DD294417A5 (de) 1991-10-02
LU91065I2 (fr) 2004-03-30
HU903045D0 (en) 1990-09-28
US5569652A (en) 1996-10-29
IE81143B1 (en) 2000-04-19
JP2848919B2 (ja) 1999-01-20
CA2016780A1 (en) 1990-11-16
ZA903754B (en) 1991-02-27
PT94038A (pt) 1991-01-08
DE3916112C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-04-30
EP0398460A2 (de) 1990-11-22
IL94416A0 (en) 1991-03-10
AU642876B2 (en) 1993-11-04
AU5509490A (en) 1990-11-22
GR3024861T3 (en) 1998-01-30
BR1101055A (pt) 2000-08-08
HU213408B (en) 1997-06-30
DE3916112A1 (de) 1990-11-22
DK0398460T3 (da) 1998-02-16
HUT54500A (en) 1991-03-28
IE901738L (en) 1990-11-16
CN1047299A (zh) 1990-11-28
EP0398460B1 (de) 1997-07-02
CN1033948C (zh) 1997-02-05

Similar Documents

Publication Publication Date Title
ES2106728T3 (es) Dihidroespirorenona como agente antiandrogeno.
EP0102534A3 (en) Hair-growing agent
BR9402902A (pt) Hormônio paratiróideo e raloxifeno, compostos e formulação farmacêutica.
ES2043025T3 (es) Un procedimiento para preparar una composicion farmaceutica que contiene acido 3-(aminopropil)metil-fosfinico como agente terapeutico.
BR9709934A (pt) Kit de terapia de reposição hormonal e/ou contraceptivo uso de unidades de dosagem diária consistindo essecialmente de um progestogênio e processo de preparação de um sistema de liberação de droga
ES2173111T3 (es) Uso de fenserina para la preparacion de medicamentos para el tratamiento de desordenes cognoscitivos.
IT1238825B (it) Dispositivo per la correzione chirurgica dell'ametropia.
DE69125855D1 (de) Therapeutisch wirksame, örtliche anwendung von st1435
IL97192A0 (en) Apparatus for surgical hyperthermia treatment of tissue,preferably the prostate,the apparatus including dilation means
GR3032224T3 (en) Therapeutic agent for threatened abortion.
NO985573L (no) Veksthormonkomponent og ben-antiresorpsjonsmiddel ved syklisk (koherens-) behandling av osteoporose
ES2040765T3 (es) Procedimiento para preparar un agente para el tratamiento de enfermedades angiogenas o tumores.
EP0408525A3 (en) Use in therapy of 10-amino-5,6-dihydro-11h-dibenzo(b,e)azepine-6,11-dione and derivatives as drugs for use in the treatment of urinary incontinence
IT1228977B (it) Apparecchio fisioterapico per la cura della sterilita' femminile accertata e per la dilatazione indolore del canale cervicale.
RU96100080A (ru) Лечение состояний, связанных с нарушением уровня паратгормона
IT1243947B (it) 2-azido-ornitina, sua preparazione e suo impiego in terapia
ATE13387T1 (de) Apparat fuer die chiropraktische therapie und massage.
IT8519276A0 (it) Procedimento per la fabbricazione di supporti plantari attrezzati, per il trattamento ortesico delle plantalgie, e supporti plantari attrezzati, cosi' ottenuti.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 398460

Country of ref document: ES

SPCR Supplementary protection certificate renounced

Free format text: ANGELIQ MOTIVO: ART. 43. 1 LEY PATENTS 11/86

Spc suppl protection certif: C200400005

Filing date: 20040312

Effective date: 20040524